Physician profile
David Heiden
NPI 1053312108
$2,335.29
in general payments reported to CMS, 2019-2025
18 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.44 · 2020: $44.83 · 2021: $247 · 2022: $1,113 · 2023: $296 · 2024: $310 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $911.92 | 2022 | |
| Abbvie INC. | $543.05 | 2022-2025 | |
| Biotissue Holdings INC. | $201.01 | 2019-2023 | |
| Ocular Therapeutix, INC. | $135.98 | 2021 | |
| Apellis Pharmaceuticals, INC. | $80.73 | 2022-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $74.08 | 2021-2023 | |
| Amgen INC. | $54.13 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $51.90 | 2022-2023 | Tepezza |
| Alcon Vision LLC | $51.72 | 2023-2025 | Eysuvis, Rocklatan |
| Bausch & Lomb Americas INC. | $47.17 | 2023 | Envista Mx60 Iol |
| Regeneron Healthcare Solutions, INC. | $41.87 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $23.82 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $23.54 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $23.45 | 2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $21.47 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $19.18 | 2024 | Vabysmo |
| Shire North American Group INC | $15.50 | 2019 | |
| Sight Sciences, INC. | $14.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Heiden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.